Myeloma Patients Europe urges CHMP committee to approve plitidepsin for relapsed myeloma

Myeloma Patients Europe (MPE) has written to the Chair of the Committee for Human Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) to provide the patient viewpoint on the importance of plitidepsin (Aplidin®) for relapsed and refractory myeloma patients across Europe. We have outlined how important it is for patients across Europe to gain access to effective drugs that have new mechanisms of action.

Update on European melphalan shortages

Melphalan (Alkeran®), a chemotherapy drug commonly used in myeloma, was not available in several European countries towards the end of 2016. Myeloma Patients Europe (MPE) became aware of the situation following reports from our members that it was impacting negatively on myeloma patients in their countries. We conducted a survey to explore the issue further, the results of which you can see here.

Delays in access to new cancer medicines and unjustifiable price rises for old ones disadvantage patients unnecessarily

Amsterdam, The Netherlands. Cancer patients are living longer and in many cases the disease is becoming chronic rather than acute. Access to drugs that help extend life and improve quality of life, and fair prices for those drugs are therefore essential for more and more people. But patients are badly served in this respect, with delays in the availability of new treatments and incomprehensible price rises for well-established therapies, including generics, according to the data…

MPE encourages EMA to review its negative recommendation for ixazomib

Myeloma Patients Europe (MPE), in close collaboration with Myeloma UK, and along with almost 30 member and non-member associations across Europe, has submitted a letter to the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency (EMA) to encourage them to reconsider the negative recommendation for ixazomib, and provide information to the appeal of their decision on ixazomib.

CHMP has expressed a negative opinion for ixazomib

Ixazomib (Ninlaro) has received a negative recommendation from the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency. The CHMP is responsible for developing recommendations for the European Commission on new medicines going through the European marketing authorisation process. It assesses and makes recommendations on whether a drug is safe and effective enough to be granted a marketing authorisation for use across the European Union. Usually the European Commission follows the advice of…